TEST:

Curebest™ 95GC Breast

No abstract available

A partial mastectomy and sentinel lymph node biopsy were performed, and the diagnosis was T2 (23 mm), N0 (sn: 0/2), M0: Stage IIA, ER positive, PgR negative, HER2 score 0, Ki-67 index: 25%, Curebest95: H. Leuprorelin was used intermittently for uterine fibroids, but menopause had not occurred, and postoperative drug therapy was continued with tamoxifen (combined with UFT2 for 2 years after surgery) to avoid hair loss...As menopausal status was confirmed, palbociclib was administered in combination with letrozole and the patient is currently under observation. Conclusion During hormone therapy for breast cancer, knee pain is often experienced as an adverse event due to the decrease in estrogen due to aging and joint deformation. In cases such as this case where conservative treatment does not improve the condition and the condition continues for a long time, a detailed examination should be considered with the exclusion of bone metastasis in mind, although this is rare

When 0-1 MGA was defined as low-risk and 2-4 MGA as high-risk, the 5-year DRFS was 97.4% for low-risk and 75.5% for high-risk (n=248, n=182, respectively; p=5.5e-11), which was a better prognostic prediction performance than any MGA alone. Discussion By performing Curebest and obtaining microarray data, it was possible to obtain the results of multiple MGAs, and it was suggested that combining each of them may enable more accurate prediction of recurrence

Among the 95 GCs, 71.4% (85/119 cases) were in the low-risk group (L), and 28.6% (34/119 cases) were in the high-risk group (H). In the L group, 1% (1/85 cases) underwent postoperative chemotherapy (CT), and the rest received only hormonal therapy (HT). In the H group, 91.2% (31/34 cases) underwent CT, and the rest received only HT.

Gallen 2013 guideline, a significant de-escalation from 73.1% (155/212) to 40.6% (86/212) in adjuvant chemotherapy was achieved. The excellent prognosis of patients with ER/HER2/n0 invasive breast cancer classified as 95GC low risk could be validated in the present registry study, indicating that 95GC is useful for safe de-escalation of adjuvant chemotherapy in patients with ER/HER2/n0 invasive breast cancer.

The 95-GC score can accurately predict RFS within 5 years of surgery for ER-positive, HER2-negative, and node-negative breast cancer using FFPE tissue samples. These prediction models could help assign patients to the most effective treatment regimen.

No abstracts available

Molecular testing, such as Oncotype DX, MammaPrint, and Curebest 95GC, have been developed to assist which breast cancer patients will benefit from the treatment. Patients with an increased level of Human Leukocyte Antigen-DR isotype, tumor-infiltrating lymphocytes, Fizzy-related protein homolog, and a decreased level of tumor-associated macrophages appear to benefit most from NACT.

"To better delineate the relapse risk in these populations, it is necessary to develop a multigene assay and validate it in a cohort comprising a higher proportion of young patients.Several multigene assays have been developed and are being used in Asian countries, including the Curebest 95 in Japan, the RecurIndex in Taiwan, and the GenesWell BCT and OncoFREE in Korea. The characteristics and clinical evidence of these multigene assays will be introduced in comparison to those widely used globally, such as the Oncotype DX, Mammaprint, Endopredict, and PAM50."

Based on the results of our retrospective study, 95GC could be used to evaluate the long-term prognosis of ER-positive, node-negative breast cancer. Even though further prospective validation is necessary, the inclusion of 95GC in clinical practice could help to select optimal treatments for breast cancer patients and identify those who do not benefit from the addition of chemotherapy, thus avoiding unnecessary treatment.

As seen with female BCa, the concordance between tests was poor, with C-index values ranging from 40.3% to 78.2% and Kappa values ranging from 0.17 to 0.58. To our knowledge, this is the largest study of male breast cancers assayed to generate risk scores of the current commercial and academic risk tests demonstrating comparable clinical utility to female BCa.

The 95-gene signature stratifies patients with ER-positive, HER2-negative, node-negative invasive breast cancer and intermediate RS of 11-25 into high and low groups that are associated with recurrence risk of invasive disease. Further retrospective analysis in the prospectively accrued TAILORx population is warranted to confirm that 95-gene signature can identify patients who would benefit from adjuvant chemoendocrine therapy.